{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:25:52Z","timestamp":1790807152724,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Non-Hodgkin B-cell lymphomas (B-NHLs) are a highly heterogeneous group of mature B-cell malignancies. Their classification thus requires skillful evaluation by expert hematopathologists, but the risk of error remains higher in these tumors than in many other areas of pathology. To facilitate diagnosis, we have thus developed a gene expression assay able to discriminate the seven most frequent B-cell NHL categories. This assay relies on the combination of ligation-dependent RT-PCR and next-generation sequencing, and addresses the expression of more than 130 genetic markers. It was designed to retrieve the main gene expression signatures of B-NHL cells and their microenvironment. The classification is handled by a random forest algorithm which we trained and validated on a large cohort of more than 400 annotated cases of different histology. Its clinical relevance was verified through its capacity to prevent important misclassification in low grade lymphomas and to retrieve clinically important characteristics in high grade lymphomas including the cell-of-origin signatures and the <jats:italic>MYC<\/jats:italic> and <jats:italic>BCL2<\/jats:italic> expression levels. This accurate pan-B-NHL predictor, which allows a systematic evaluation of numerous diagnostic and prognostic markers, could thus be proposed as a complement to conventional histology to guide the management of patients and facilitate their stratification into clinical trials.<\/jats:p>","DOI":"10.1038\/s41408-020-0322-5","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T13:04:05Z","timestamp":1590152645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9357-4542","authenticated-orcid":false,"given":"Victor","family":"Bob\u00e9e","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Drieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinciane","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"Veresezan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Picquenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Julien","family":"Viailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Delphine","family":"Lanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Viennot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-576X","authenticated-orcid":false,"given":"Elodie","family":"Bohers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Oberic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Copie-Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry Jo","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gaulard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ruminy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"322_CR1","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","volume":"35","author":"C Laurent","year":"2017","unstructured":"Laurent, C. et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the french lymphopath network. J. Clin. Oncol. 35, 2008\u20132017 (2017).","journal-title":"J. Clin. Oncol."},{"key":"322_CR2","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1200\/JCO.2010.31.2223","volume":"29","author":"IE Proctor","year":"2011","unstructured":"Proctor, I. E., McNamara, C., Rodriguez-Justo, M., Isaacson, P. G. & Ramsay, A. Importance of expert central review in the diagnosis of lymphoid malignancies in a regional cancer network. J. Clin. Oncol. 29, 1431\u20131435 (2011).","journal-title":"J. Clin. Oncol."},{"key":"322_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/bjh.12880","volume":"166","author":"JM Bowen","year":"2014","unstructured":"Bowen, J. M. et al. Lymphoma diagnosis at an academic centre: rate of revision and impact on patient care. Br. J. Haematol. 166, 202\u2013208 (2014).","journal-title":"Br. J. Haematol."},{"key":"322_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/annonc\/mdr029","volume":"23","author":"MJ Matasar","year":"2012","unstructured":"Matasar, M. J. et al. Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification. Ann. Oncol. 23, 159\u2013166 (2012).","journal-title":"Ann. Oncol."},{"key":"322_CR5","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","volume":"123","author":"DW Scott","year":"2014","unstructured":"Scott, D. W. et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123, 1214\u20131217 (2014).","journal-title":"Blood"},{"key":"322_CR6","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.jmoldx.2017.07.007","volume":"19","author":"V Bob\u00e9e","year":"2017","unstructured":"Bob\u00e9e, V. et al. Determination of molecular subtypes of diffuse large B-Cell lymphoma using a reverse transcriptase multiplex ligation-dependent probe amplification classifier: A CALYM Study. Mol. Diagn. 19, 892\u2013904 (2017).","journal-title":"Mol. Diagn."},{"key":"322_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/bjh.15518","volume":"183","author":"H Holte","year":"2018","unstructured":"Holte, H. et al. The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy. Br. J. Haematol. 183, 225\u2013234 (2018).","journal-title":"Br. J. Haematol."},{"key":"322_CR8","unstructured":"Swerdlow S. H., et al. Mature B-cell neoplasms. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised fourth edition) 215\u2013342. (IARC, Lyon 2017)."},{"key":"322_CR9","doi-asserted-by":"publisher","first-page":"46071","DOI":"10.18632\/oncotarget.17551","volume":"8","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. A high-throughput method to detect RNA profiling by integration of RT-MLPA with next generation sequencing technology. Oncotarget 8, 46071\u201346080 (2017).","journal-title":"Oncotarget"},{"key":"322_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1084\/jem.20031074","volume":"198","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald, A. et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198, 851\u2013862 (2003).","journal-title":"J. Exp. Med."},{"key":"322_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrc1589","volume":"5","author":"R K\u00fcppers","year":"2005","unstructured":"K\u00fcppers, R. Mechanisms of B-cell lymphoma pathogenesis. Nat. Rev. Cancer 5, 251\u2013262 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"322_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc3774","volume":"14","author":"DW Scott","year":"2014","unstructured":"Scott, D. W. & Gascoyne, R. D. The tumour microenvironment in B cell lymphomas. Nat. Rev. Cancer 14, 517\u2013534 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"322_CR13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3324\/haematol.2014.113472","volume":"100","author":"S Riihij\u00e4rvi","year":"2015","unstructured":"Riihij\u00e4rvi, S. et al. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica 100, 238\u2013245 (2015).","journal-title":"Haematologica"},{"key":"322_CR14","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.3109\/10428194.2013.879713","volume":"55","author":"SJ Nam","year":"2014","unstructured":"Nam, S. J. et al. An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. Leuk. Lymphoma. 55, 2466\u20132476 (2014).","journal-title":"Leuk. Lymphoma."},{"key":"322_CR15","first-page":"1640","volume":"8","author":"E Matutes","year":"1994","unstructured":"Matutes, E. et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8, 1640\u20131645 (1994).","journal-title":"Leukemia"},{"key":"322_CR16","doi-asserted-by":"publisher","first-page":"3797","DOI":"10.1182\/blood-2013-10-534073","volume":"123","author":"U Rozovski","year":"2014","unstructured":"Rozovski, U. et al. Stimulation of the B-cell receptor activates the JAK2\/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 123, 3797\u20133802 (2014).","journal-title":"Blood"},{"key":"322_CR17","doi-asserted-by":"publisher","first-page":"6341","DOI":"10.1073\/pnas.96.11.6341","volume":"96","author":"T Yamadori","year":"1999","unstructured":"Yamadori, T. et al. Bruton\u2019s tyrosine kinase activity is negatively regulated by Sab, the Btk-SH3 domain-binding protein. Proc. Natl Acad. Sci. USA 96, 6341\u20136346 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"322_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/ejh.12539","volume":"95","author":"S-J Shin","year":"2015","unstructured":"Shin, S.-J. et al. TCL1 expression predicts overall survival in patients with mantle cell lymphoma. Eur. J. Haematol. 95, 583\u2013594 (2015).","journal-title":"Eur. J. Haematol."},{"key":"322_CR19","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1038\/leu.2009.144","volume":"23","author":"A Farfsing","year":"2009","unstructured":"Farfsing, A. et al. Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia. Leukemia 23, 2018\u20132026 (2009).","journal-title":"Leukemia"},{"key":"322_CR20","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","volume":"113","author":"AV Kurtova","year":"2009","unstructured":"Kurtova, A. V., Tamayo, A. T., Ford, R. J. & Burger, J. A. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 113, 4604\u20134613 (2009).","journal-title":"Blood"},{"key":"322_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1084\/jem.20062041","volume":"204","author":"G Lenz","year":"2007","unstructured":"Lenz, G. et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J. Exp. Med. 204, 633\u2013643 (2007).","journal-title":"J. Exp. Med."},{"key":"322_CR22","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/leu.2010.302","volume":"25","author":"P Ruminy","year":"2011","unstructured":"Ruminy, P. et al. The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma. Leukemia 25, 681\u2013688 (2011).","journal-title":"Leukemia"},{"issue":"12","key":"322_CR23","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1158\/1078-0432.CCR-15-2305","volume":"22","author":"S. Dubois","year":"2016","unstructured":"Dubois, S., et al. Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA Study. Clin. Cancer Res. 22, 2919\u20132928 (2016).","journal-title":"Clinical Cancer Research"},{"key":"322_CR24","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","volume":"35","author":"AM Staiger","year":"2017","unstructured":"Staiger, A. M. et al. Clinical impact of the cell-of-origin classification and the MYC\/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the german high-grade non-Hodgkin\u2019s lymphoma study group. J. Clin. Oncol. 35, 2515\u20132526 (2017).","journal-title":"J. Clin. Oncol."},{"key":"322_CR25","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","volume":"30","author":"TM Green","year":"2012","unstructured":"Green, T. M. et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 30, 3460\u20133467 (2012).","journal-title":"J. Clin. Oncol."},{"key":"322_CR26","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson, N. A. et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 30, 3452\u20133459 (2012).","journal-title":"J. Clin. Oncol."},{"key":"322_CR27","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","volume":"33","author":"DW Scott","year":"2015","unstructured":"Scott, D. W. et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J. Clin. Oncol. 33, 2848\u20132856 (2015).","journal-title":"J. Clin. Oncol."},{"key":"322_CR28","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1182\/blood-2016-11-747022","volume":"129","author":"D Ennishi","year":"2017","unstructured":"Ennishi, D. et al. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood 129, 2760\u20132770 (2017).","journal-title":"Blood"},{"key":"322_CR29","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.3109\/10428194.2016.1167205","volume":"57","author":"H Takahashi","year":"2016","unstructured":"Takahashi, H. et al. Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy. Leuk. Lymphoma 57, 2784\u20132790 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"322_CR30","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","volume":"133","author":"AD Zelenetz","year":"2019","unstructured":"Zelenetz, A. D. et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood 133, 1964\u20131976 (2019).","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0322-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:28:41Z","timestamp":1670250521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0322-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["322"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0322-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]},"assertion":[{"value":"6 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.B., V.M., F.J., and P.R. are named inventor on a pending patent describing gene expression profiling classification in lymphoma. Other authors have no conflict of interest relevant to this study to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"59"}}